•   
  •   
  •   

Sport Coronavirus vaccines: How J&J's is different from the others

02:17  28 february  2021
02:17  28 february  2021 Source:   msn.com

UK asks for volunteers to be exposed to COVID-19 for research

  UK asks for volunteers to be exposed to COVID-19 for research An ethics committee has approved the U.K.'s COVID-19 human challenge study. Now, researchers are calling for volunteers, as the trials are slated to start within a month.

The United States is poised to get a third coronavirus vaccine -- this one made by Johnson & Johnson.

With Johnson & Johnson' s Covid-19 vaccine on the verge of being authorized for emergency use by the US Food and Drug Administration, Americans are taking another look at the vaccine and it' s data. And what they see might initially give them pause. That' s not how this was done." The vaccines were also tested at different times, she said, and different types of strains were more prevalent than others depending on the location. Notably, Johnson & Johnson' s vaccine was tested in South Africa, where the dominant strain was the B.1.351 variant, which is believed to be more contagious.

The United States is poised to get a third coronavirus vaccine -- this one made by Johnson & Johnson.

a close up of a person holding a cell phone: A healthcare worker holds the Johnson & Johnson vaccine against the COVID-19 coronavirus before administaring it to another healthcare worker as South Africa proceeds with its inoculation campaign at the Steve Biko Academic Hospital in Pretoria on February 17, 2021. © Phill Magakoe/AFP/Getty Images A healthcare worker holds the Johnson & Johnson vaccine against the COVID-19 coronavirus before administaring it to another healthcare worker as South Africa proceeds with its inoculation campaign at the Steve Biko Academic Hospital in Pretoria on February 17, 2021.

The US Food and Drug Administration has given the vaccine emergency use authorization, and J&J is scheduled to start distribution next week.

Two vaccines are already being distributed in the US -- one made by Moderna and another made by Pfizer and its German partner BioNTech. The new vaccine, made by Johnson & Johnson's Janssen vaccine division, is a little different. Here's how.

The Latest: Malaysia begins vaccinations, PM gets 1st shot

  The Latest: Malaysia begins vaccinations, PM gets 1st shot KUALA LUMPUR, Malaysia — Prime Minister Muhyiddin Yassin received Malaysia’s first COVID-19 vaccine shot on Wednesday at the start of its inoculation campaign. “I did not feel anything at all. It was all over before I realized, just like a normal injection. Don’t worry, come forward anytime,” he said at a ceremony broadcast live. Health Director-General Noor Hisham Abdullah was also among the first to be vaccinated. Malaysia, which has signed deals with several vaccine suppliers including Pfizer and AstroZeneca, aims to vaccinate up to 80% of its 32 million people by next year.

Unlike the other two, J & J ’ s vaccine can be stored in normal refrigerator temperatures instead of ultra-cold storage. That makes distribution a lot easier. Brazil's Health Ministry on Thursday signed a contract to purchase 20 million doses of Covaxin, the COVID-19 vaccine made by India's Bharat Biotech, for delivery between March and May. To speed up the buying of vaccines in Brazil and deal with the second-deadliest coronavirus outbreak in the world, the ministry said it published new rules last week dispensing with the bidding process.

J & J ’ s vaccine is different from the messenger RNA-based shots made by Moderna and partners Pfizer and BioNTech SE. It is based on an adenovirus, or cold germ modified to make copies of the coronavirus spike protein, which the pathogen uses to force its way into cells. So, how should investors approach a potential penny stock investment? By taking a cue from the analyst community. These experts bring in-depth knowledge of the industries they cover and substantial experience to the table.

It's one dose

Johnson & Johnson's vaccine is designed to be given as a single dose. That means no follow-up visits, none of the red tape needed to make sure people return for those second shots, and none of the worry about making sure a second dose is available at the right time.

The Pfizer and Moderna vaccines are both designed to be given in a two-dose series -- the Pfizer vaccine three weeks apart and Moderna's four weeks apart. There's been discussion about whether it might be OK to give these vaccines as a single dose, or to extend the time between doses so more people can get their first vaccine, and thus get at least some protection.

But the FDA authorization says two doses, and many vaccine experts, including White House chief medical adviser Dr. Anthony Fauci, fear giving just one dose of Pfizer and Moderna's vaccines might leave people only partly protected.

9 Reasons to Believe the Worst of the Pandemic Is Over

  9 Reasons to Believe the Worst of the Pandemic Is Over The good news is really starting to roll in. (Though there are also a few reasons for caution.)The horrifying surge of coronavirus cases that began last fall has now abated. Two months after the first two COVID vaccines began going into American arms, studies continue to emphasize how remarkably effective they are. And after a haphazard start, the country’s mass-vaccination effort is continuing to ramp up. Suddenly, the latest wave of the pandemic is one of cautious optimism regarding the near future.

J & J ’ s vaccine protects against the worst effects of COVID-19 after one shot, and it can be stored up to three months at refrigerator temperatures, making it easier to handle than the previous vaccines , which must be frozen. One challenge in rolling out the new vaccine will be explaining how protective the J & J shot is after the astounding While J & J is seeking FDA authorization for its single-dose version, the company is also studying whether a second dose boosts protection. Panel member Dr. Paul Offit warned that launching a two-dose version of the vaccine down the road might cause problems.

Unlike the other two, J & J ’ s vaccine can be stored in normal refrigerator temperatures instead of ultra-cold storage. That makes distribution a lot easier. A trial found that J & J ’ s vaccine was 66% effective at preventing moderate-to-severe cases of COVID-19. And it was 100% effective at preventing Subscribe for free.White House coronavirus coordinator Jeff Zients said on Wednesday that J & J will have 3 million to 4 million ready for distribution next week.The Moderna and Pfizer-BioNtech shots are the only other vaccines that have received FDA authorization. Unlike Moderna's shot, J & J ' s vaccine

Johnson & Johnson's vaccine was tested and shown to protect people with a single dose, although studies are underway to see if two doses might provide more protection.

Different efficacy

One thing people might notice right away about the Johnson & Johnson vaccine is how it stacks up against Pfizer's and Moderna's in terms of efficacy. Those vaccines had a startling efficacy rate in clinical trials of 94% to 95%. Real-world studies of Pfizer's vaccine in Israel indicate that efficacy holds up. The risk of symptomatic Covid-19 -- meaning people who got infected with the coronavirus and felt sick -- decreased by 94% among people given two doses of the vaccine.

In contrast, the overall global efficacy of Janssen's vaccine was 66% against moderate to severe illness. But it was 85% effective against severe disease and, in trials anyway, 100% effective at preventing death, as no one who got the vaccine died from Covid-19.

Johnson & Johnson COVID vaccine cleared for expected FDA authorization within days

  Johnson & Johnson COVID vaccine cleared for expected FDA authorization within days If the FDA agrees with its review panel, as expected, the one-dose vaccine could begin rolling out to the American public next week."I think authorization of this vaccine will help meet the needs at the moment," committee member Dr. Archana Chatterjee, dean of the Chicago Medical School, said after casting her vote.

During J & J ’ s first quarter earnings call, Chief Scientific Officer Paul Stoffels said the company is also negotiating with partners in Europe and Asia to produce the vaccine , and partnerships will be announced in the coming weeks. J & J Chief Scientific Officer Dr. Paul Stoffels describes how the pharmaceutical company is developing a coronavirus vaccine to fight COVID-19. J & J entered into a billion partnership with the US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) to develop and manufacture the vaccine .

As the global race to produce a Covid-19 vaccine continues, China appears to have made huge strides, with vaccines from two front-runners - Sinovac and Sinopharm - already making their way abroad. But what do we know about China' s vaccines and how do they compare to those being developed elsewhere? By comparison the Moderna and Pfizer vaccines being developed in the West are mRNA vaccines . This means part of the coronavirus ' genetic code is injected into the body, triggering the body to begin making viral proteins, but not the whole virus, which is enough to train the immune

The Johnson & Johnson vaccine was given in different populations and at a different time, however. It was tested in 44,000 people in the US, South Africa and Latin America, and most of the testing was months later in the pandemic than the Pfizer and Moderna vaccines, which started testing in the spring and summer.

Pfizer's vaccine was tested in 43,000 people in the United States, Germany, Turkey, South Africa, Brazil and Argentina. Moderna's was tested in 30,000 people, all of them in the US.

The Johnson & Johnson vaccine was tested after some of the troubling new coronavirus variants had started to circulate, including one first seen in South Africa, called B.1.351, that appears to weaken the body's recognition of the virus -- including after vaccination. The Johnson & Johnson vaccine's efficacy was just 57% in South Africa, where B.1.351 is now the dominant variant, compared to 72% in the US, where it is far less common.

Vaccine experts agree that all the vaccines provide very good protection by the most important measure, which is whether they keep people from getting seriously ill.

Indonesia courts controversy with private COVID vaccine scheme

  Indonesia courts controversy with private COVID vaccine scheme Health experts question plan to allow private companies to import vaccines to ‘speed up’ effort to reach herd immunity.The country is aiming to vaccinate 181.5 million out of the 270 million population by 2021. But since the public rollout began on January 13, only one million people have been fully vaccinated with two doses, according to Our World in Data, an online resource tracking global COVID-19 vaccination releases. Nearly 2.7 million have had their first jab.

But the differing efficacies raise the possibility that some people will see the Johnson & Johnson vaccine as second class, Sarah Christopher, the policy advocacy director at the National Women's Health Network, told an FDA advisory committee meeting Friday.

There are feelings "that there are first and second class vaccines, with the latter relegated to low income, rural, or otherwise marginalized communities that has the potential to exacerbate existing mistrust," she said. "Public health authorities must address these perceptions head on."

Quicker protection

With the Johnson & Johnson vaccine, protection against moderate to severe disease starts about two weeks after people get vaccinated. By four weeks after the shot, data from the clinical trial showed there were no hospitalizations or deaths.

Recent studies show good level of protection with the first dose of the Moderna and Pfizer vaccines, but people don't get full protection until about two weeks after the second dose -- so five to six weeks after the first dose.

It's made using different technology

The Moderna and Pfizer vaccines use a brand-new technology called messenger RNA, or mRNA. They deliver genetic material directly into cells via fatty particles. That genetic code gets taken up by cells in the arm muscle, which then follow the genetic instructions to make tiny pieces that look like a part of the coronavirus.

COVID shows infectious disease is our greatest threat to global security

  COVID shows infectious disease is our greatest threat to global security Unlike traditional security threats, infectious disease can’t be solved through sanctions, military posturing, deterrence or bilateral diplomacy, but rather through scientific collaboration, long-term investments in global health and resilient health systems and through smart and strategic multilateralism. While this may come too late to prevent the current pandemic, we do now at least have a powerful solution to this crisis - thanks to the unprecedented speed at which the scientific community and industry have responded - vaccines.

Those little proteins stimulate an immune response, generating antibodies and immune cells that "remember" what they look like and that will be ready to respond quickly in case of a fresh attack.

The Johnson & Johnson vaccine uses viral vector technology. A common cold virus called adenovirus 26 is genetically engineered so that it can infect cells, but it won't replicate there. It cannot spread in the body, and won't give people a cold. Like the Pfizer and Moderna vaccines, it delivers genetic instructions.

Instead of being carried in little lipid balls, the genetic instructions are injected by the weakened virus into arm cells, and they make the pieces that look like part of the coronavirus spike protein -- the knob-shaped structure that the virus uses to connect to cells.

It's easier to handle

Those delicate little balls of fat used to carry the Moderna and Pfizer vaccines need careful handling. Pfizer's vaccine must be stored and shipped at between -80ºC to -60ºC (-112ºF to -76ºF) -- something that caused a lot of trouble for states at first, which had to scramble to get dry ice and special freezers. The FDA has now eased up on those requirements a bit, but the vaccine can still only be held in the refrigerator for five days and must be used within six hours of being thawed and diluted.

And yes, the Pfizer vaccine must be diluted before it's used, and it cannot be shaken, but must be carefully inverted exactly 10 times to mix it. The Moderna vaccine is a little less fussy but also must be frozen and carefully handled.

Moderna's vaccine can be kept at about -20ºC, or about the temperature of a home freezer.

In contrast, Johnson & Johnson's vaccine can be kept at simple refrigerator temperatures, making it far easier to store and ship.

What they have in common

None of the three vaccines contains additives that can sometimes cause strong reactions, such as antibiotics, preservatives or adjuvants, which are compounds used to boost the immune response that can add to the kick of any vaccine.

That means a very low risk of allergic reaction, especially life-threatening anaphylaxis. The CDC reports only a few cases of anaphylaxis in people who have been given the Moderna or Pfizer vaccines, and all were easily treated.

Only one case of anaphylaxis has been reported in the 44,000 people who have tested the Johnson & Johnson vaccine.

Plus, all three target a specific part of the spike protein called the receptor binding domain. As the name implies, it's the part the virus uses to grapple cells. Mutations to this particular region could weaken the efficacy of all three vaccines.

Luckily, all three appear to stimulate an overwhelming immune response -- one much stronger than people get after a natural infection. So far, it appears to be enough to continue at least partially protecting people from the most concerning variants.

Relaxing restrictions, Food Night, mass vaccine sites: News from around our 50 states .
How the COVID-19 pandemic is affecting every stateStart the day smarter. Get all the news you need in your inbox each morning.

usr: 1
This is interesting!